These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 10848822)
1. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822 [TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA. Haj MA; Robbie LA; Croll A; Adey GD; Bennett B Intensive Care Med; 1998 Mar; 24(3):258-61. PubMed ID: 9565810 [TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706 [TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
5. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909 [TBL] [Abstract][Full Text] [Related]
6. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Declerck PJ; Verstreken M; Collen D Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114 [TBL] [Abstract][Full Text] [Related]
7. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]. Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755 [TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Nakashima A; Kobayashi T; Terao T Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712 [TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943 [TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655 [TBL] [Abstract][Full Text] [Related]
11. Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors. Mukherjee M; Sembhi K; Kakkar VV Blood Coagul Fibrinolysis; 1996 Jun; 7(4):491-6. PubMed ID: 8840003 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts. Xiao Y; Bunn CL; Bartold PM J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317 [TBL] [Abstract][Full Text] [Related]
13. The expression of plasminogen activator system in a rat model of periodontal wound healing. Xiao Y; Li H; Bunn C; Bartold PM J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131 [TBL] [Abstract][Full Text] [Related]
14. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits. Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381 [TBL] [Abstract][Full Text] [Related]
15. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. Wallnöfer AE; van Griensven JM; Schoemaker HC; Cohen AF; Lambert W; Kluft C; Meijer P; Kooistra T Thromb Haemost; 1993 Dec; 70(6):1005-8. PubMed ID: 8165591 [TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females. Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623 [TBL] [Abstract][Full Text] [Related]
17. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665 [TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Casslén B; Bossmar T; Lecander I; Astedt B Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418 [TBL] [Abstract][Full Text] [Related]
20. Factors involved in the plasminogen activation system in human breast tumours. Damjanovich L; Turzó C; Adány R Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]